• 1. An amino group functionalized metal–organic framework as a luminescent probe for highly selective sensing of Fe3+ ions?
  Zhonghua Xiang,Chuanqi Fang,Sanhua Leng,Dapeng Cao J. Mater. Chem. A, 2014,2, 7662-7665
• 2. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 3. Aggregated-fluorescent detection of PFAS with a simple chip
  Cheng Fang,Jinjian Wu,Zahra Sobhani,Md. Al Amin,Youhong Tang Anal. Methods, 2019,11, 163-170
• 4. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 5. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Coumarins and derivatives Linear furanocoumarins
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Coumarins and derivatives Furanocoumarins Linear furanocoumarins

Professional Introduction to Compound with CAS No. 89560-97-4 and Product Name t-OMe-Byakangelicin

Compound with the CAS number 89560-97-4 is a chemically significant molecule that has garnered considerable attention in the field of pharmaceutical and biochemical research. The product name, t-OMe-Byakangelicin, refers to a specific derivative of Byakangelicin, a naturally occurring flavonoid found in traditional medicinal plants such as *Pterriopis trifoliata* (Japanese angelica). This compound has been the subject of extensive studies due to its potential biological activities and structural uniqueness.

The chemical structure of t-OMe-Byakangelicin features a methoxyl group at the 7-position of the flavonoid backbone, which enhances its solubility and bioavailability compared to its parent compound. This modification has been shown to significantly influence its pharmacokinetic properties, making it a more viable candidate for therapeutic applications. Recent advancements in computational chemistry have allowed researchers to predict the binding interactions of t-OMe-Byakangelicin with various biological targets, providing insights into its mechanism of action.

One of the most promising areas of research involving t-OMe-Byakangelicin is its anti-cancer properties. Studies have demonstrated that this compound can induce apoptosis in several cancer cell lines by inhibiting key signaling pathways such as the PI3K/Akt and MAPK pathways. The methoxyl group in t-OMe-Byakangelicin plays a crucial role in stabilizing its interactions with these targets, thereby enhancing its efficacy. Additionally, preclinical trials have shown that t-OMe-Byakangelicin exhibits lower toxicity profiles compared to conventional chemotherapeutic agents, making it an attractive option for combination therapies.

In addition to its anti-cancer properties, t-OMe-Byakangelicin has also been investigated for its potential anti-inflammatory and neuroprotective effects. Research indicates that this compound can modulate inflammatory responses by inhibiting the production of pro-inflammatory cytokines such as TNF-α and IL-6. Furthermore, studies have suggested that t-OMe-Byakangelicin may protect against neurodegenerative diseases by reducing oxidative stress and preventing the aggregation of misfolded proteins associated with conditions like Alzheimer's disease.

The synthesis of t-OMe-Byakangelicin has been optimized through various chemical methodologies, including enzymatic glycosylation and palladium-catalyzed cross-coupling reactions. These synthetic approaches have not only improved the yield and purity of the compound but also reduced the environmental impact of its production. The growing interest in green chemistry has spurred efforts to develop sustainable synthetic routes for natural product derivatives like t-OMe-Byakangelicin, ensuring that future research can be conducted in an environmentally responsible manner.

Recent studies have also explored the pharmacokinetic behavior of t-OMe-Byakangelicin using advanced metabolomics techniques. These studies have revealed that the compound undergoes extensive metabolic conversion in vivo, primarily through Phase II biotransformation processes such as glucuronidation and sulfation. Understanding these metabolic pathways is crucial for optimizing drug delivery systems and minimizing potential side effects. For instance, prodrugs designed to enhance the bioavailability of t-OMe-Byakangelicin have shown promise in preclinical models, demonstrating improved therapeutic efficacy.

The regulatory landscape for compounds like t-OMe-Byakangelicin is continually evolving, with agencies such as the FDA and EMA implementing stricter guidelines for drug development. Clinical trials are now required to provide comprehensive data on safety, efficacy, and pharmacokinetics before a new drug can be approved for market use. Despite these challenges, the growing body of evidence supporting the therapeutic potential of t-OMe-Byakangelicin has fueled enthusiasm among researchers and pharmaceutical companies alike.

In conclusion, t-OMe-Byakangelicin, derived from Compound with CAS No. 89560-97-4, represents a significant advancement in natural product-based drug development. Its unique chemical structure, combined with promising preclinical results, positions it as a strong candidate for further clinical investigation. As research continues to uncover new applications and optimize synthetic methodologies, compounds like t-OMe-Byakangelicin are poised to play a vital role in addressing some of today's most pressing medical challenges.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)